Acknowledgments

This work was partially supported by Grant NIH P41-001975, "Resource Facility for Population Kinetics."

Regulatory Mechanisms

Regulatory Mechanisms

Gene Expression

Figure 21.3 Modeling and simulation in the general context of the study of xenobiot-ics. The network of signals and regulatory pathways, sources of variability, and multistep regulation that are involved in this problem is shown together with its main components. It is important to realize how between-subject and between-event variation must be addressed in a model of the system that is not purely structural, but also statistical. The power of model-based data analysis is to elucidate the (main) subsystems and their putative role in overall regulation, at a variety of life stages, species, and functional (cell to organismal) levels. Images have been selected for illustrative purposes only. See color plate.

Gene Expression

Figure 21.3 Modeling and simulation in the general context of the study of xenobiot-ics. The network of signals and regulatory pathways, sources of variability, and multistep regulation that are involved in this problem is shown together with its main components. It is important to realize how between-subject and between-event variation must be addressed in a model of the system that is not purely structural, but also statistical. The power of model-based data analysis is to elucidate the (main) subsystems and their putative role in overall regulation, at a variety of life stages, species, and functional (cell to organismal) levels. Images have been selected for illustrative purposes only. See color plate.

REFERENCES

1. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004;3:739-48.

2. Aebersold R, Hood LE, Watts JD. Equipping scientists for the new biology. Nat Biotechnol 2000;18:359.

3. Guyton AC. Human physiology and mechanisms of disease, 4th Ed. Philadelphia: W. B. Saunders, 1987.

4. Westerhoff HV, Palsson BO. The evolution of molecular biology into systems biology. Nat Biotechnol 2004;22:1249-52.

5. NIH Roadmap for Medical Research, http://nihroadmap.nih.gov/ (accessed October 1, 2005).

6. NOT-OD-05-002: NIH Announces Updated Criteria for Evaluating Research Grant Applications, http://grants.nih.gov/grants/guide/notice-files/NOT-OD-05-002.html (accessed October 1, 2005).

7. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Exposure-Response Relationships—Study Design, Data Analysis, and Regulatory Applications. http://www.fda.gov/cder/guidance/5341fnl.pdf (accessed October 1, 2005).

8. Preusch PC. Integrative and organ systems pharmacology: a new initiative from the National Institute of General Medical Sciences. Mol Interv 2004;4:72-3.

9. Crampin EJ, Smith NP, Hunter PJ. Multi-scale modelling and the IUPS physiome project. J Mol Histol 2004;35:707-14.

10. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Population Pharmacokinetics. http://www.fda.gov/cder/guidance/1852fnl.pdf (accessed October 1, 2005).

11. Notice: Approaches for the Application of Physiologically-Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment E-Docket ID No. ORD-2005-0022. Fed Reg July 28, 2005;70 (144): 43692-43693.

12. Dourson ML, Andersen ME, Erdreich LS, MacGregor JA. Using human data to protect the public's health. Regul Toxicol Pharmacol 2001;33:234-56.

13. The Virtual Soldier Project, http://www.virtualsoldier.net/ (accessed October 4, 2005).

14. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000;40:67-95.

15. Chan PL, Holford NH. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 2001;41:625-59.

16. Jang GR, Harris RZ, Lau DT. Pharmacokinetics and its role in small molecule drug discovery research. Med Res Rev 2001;21:382-96.

17. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992;32:185-209.

18. Sheiner L, Wakefield J. Population modelling in drug development. Stat Methods Med Res 1999;8:183-93.

19. Gieschke R, Reigner BG, Steimer JL. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther 1997;35:469-74.

20. Bonate PL. Clinical trial simulation in drug development. Pharm Res 2000;17:252-6.

21. Rowland M. Physiologic pharmacokinetic models: relevance, experience, and future trends. Drug Metab Rev 1984;15:55-74.

22. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003;42: 883-908.

23. Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 1994;22:431-45.

24. Holford NHG, Hale M, Ko HC, Steimer J-L, Sheiner LB, Peck CC et al. Simulation in Drug Development: Good Practices. Draft Publication of the Center for Drug Development Science (CDDS) Draft version 1.0, July 23, 1999, http://cdds.georgetown.edu/research/sddgp723.html (accessed October 1, 2005)

25. Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci 2004;6:E6.

26. Nestorov I. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 2001;120:411-20.

27. Hunter PJ, Borg TK. Integration from proteins to organs: the Physiome Project. Nat Rev Mol Cell Biol 2003;4:237-43.

28. Nestorov IA, Aarons LJ, Rowland M. Physiologically based pharmacokinetic modeling of a homologous series of barbiturates in the rat: a sensitivity analysis. J Pharmacokinet Biopharm 1997;25:413-47.

29. West GB, Woodruff WH, Brown JH. Allometric scaling of metabolic rate from molecules and mitochondria to cells and mammals. Proc Natl Acad Sci USA 2002;99 Suppl 1:2473-8.

30. Cousineau D, Rose CP, Lamoureux D, Goresky CA. Changes in cardiac trans-capillary exchange with metabolic coronary vasodilation in the intact dog. Circ Res 1983;53:719-30.

31. Goresky CA. Kinetic interpretation of hepatic multiple-indicator dilution studies. Am J Physiol Gastrointest Liver Physiol 1983;245:G1-G12.

32. Goresky CA, Rose CP. Blood-tissue exchange in liver and heart: the influence of heterogeneity of capillary transit times. Fed Proc 1977;36:2629-34.

33. Kainer R. A functional model of the rat kidney. J Math Biol 1979;7:57-94.

34. Kassissia IG, Goresky CA, Rose CP, Schwab AJ, Simard A, Huet PM, Bach GG. Tracer oxygen distribution is barrier-limited in the cerebral microcirculation. Circ Res 1995;77:1201-11.

35. Goresky CA. A linear method for determining liver sinusoidal and extravascular volumes. Am J Physiol 1963;204:626-40.

36. Tirona RG, Schwab AJ, Geng W, Pang KS. Hepatic clearance models: comparison of the dispersion and Goresky models in outflow profiles from multiple indicator dilution rat liver studies. Drug Metab Dispos 1998;26:465-75.

37. Bassingthwaighte JB, Sparks HV. Indicator dilution estimation of capillary endothelial transport. Annu Rev Physiol 1986;48:321-34.

38. Bassingthwaighte JB, Wang CY, Chan IS. Blood-tissue exchange via transport and transformation by capillary endothelial cells. Circ Res 1989;65:997-1020.

39. Muzikant AL, Penland RC. Models for profiling the potential QT prolongation risk of drugs. Curr Opin Drug Discov Devel 2002;5:127-35.

40. Pharmacokinetic and Pharmacodynamic Resources, http://www.boomer.org/ pkin/ (accessed October 1, 2005)

41. Center for Modeling Integrated Metabolic Systems (MIMS), http://www.csuohio. edu/mims/ (accessed October 1, 2005)

42. Popel AS, Pries AR, Slaaf DW. Microcirculation Physiome Project. J Vasc Res 1999;36:253-5.

43. Bassingthwaighte JB, Qian H, Li Z. The Cardiome Project. An integrated view of cardiac metabolism and regional mechanical function. Adv Exp Med Biol 1999;471:541-53.

44. Lazebnik Y. Can a biologist fix a radio? Or, what I learned while studying apop-tosis. Cancer Cell 2002;2:179-82.

45. Loew LM, Schaff JC. The Virtual Cell: a software environment for computational cell biology. Trends Biotechnol 2001;19:401-6.

46. National Resource for Cell Analysis and Modeling (NRCAM), home of the Virtual Cell, http://www.nrcam.uchc.edu/ (accessed October 2, 2005)

47. Slepchenko BM, Schaff JC, Macara I, Loew LM. Quantitative cell biology with the Virtual Cell. Trends Cell Biol 2003;13:570-6.

48. CellML, http://www.cellml.org/ (accessed October 2, 2005).

49. Price ND, Papin JA, Schilling CH, Palsson BO. Genome-scale microbial in silico models: the constraints-based approach. Trends Biotechnol 2003;21:162-9.

50. Famili I, Forster J, Nielsen J, Palsson BO. Saccharomyces cerevisiae phenotypes can be predicted by using constraint-based analysis of a genome-scale reconstructed metabolic network. Proc Natl Acad Sci USA 2003;100:13134-9.

51. Ibarra RU, Edwards JS, Palsson BO. Escherichia coli K-12 undergoes adaptive evolution to achieve in silico predicted optimal growth. Nature 2002;420:186-9.

52. Schilling CH, Covert MW, Famili I, Church GM, Edwards JS, Palsson BO. Genome-scale metabolic model of Helicobacter pylori 26695. J Bacteriol 2002;184:4582-93.

53. Papin JA, Hunter T, Palsson BO, Subramaniam S. Reconstruction of cellular signalling networks and analysis of their properties. Nat Rev Mol Cell Biol 2005;6:99-111.

54. Panetta JC, Wall A, Pui CH, Relling MV, Evans WE. Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin Cancer Res 2002;8:2423-9.

55. Panetta JC, Yanishevski Y, Pui CH, Sandlund JT, Rubnitz J, Rivera GK et al. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2002;50:419-28.

56. Park S, Yang X, Saven JG. Advances in computational protein design. Curr Opin Struct Biol 2004;14:487-94.

57. Kuhlman B, Dantas G, Ireton GC, Varani G, Stoddard BL, Baker D. Design of a novel globular protein fold with atomic-level accuracy. Science 2003;302: 1364-8.

58. Erickson J, Neidhart DJ, VanDrie J, Kempf DJ, Wang XC, Norbeck DW et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor com-plexed to HIV-1 protease. Science 1990;249:527-33.

59. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.

60. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.

61. Van der Graaf PH, Nilsson J, Van Schaick EA, Danhof M. Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat. J Pharm Sci 1999;88:306-12.

62. Fouchecourt MO, Beliveau M, Krishnan K. Quantitative structure-pharmacokinetic relationship modelling. Sci Total Environ 2001;274:125-35.

63. Mager DE, Jusko WJ. Quantitative structure-pharmacokinetic/pharmacody-namic relationships of corticosteroids in man. J Pharm Sci 2002;91:2441-51.

64. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005;37:435-40.

65. Meir E, Munro EM, Odell GM, Von Dassow G. Ingeneue: a versatile tool for reconstituting genetic networks, with examples from the segment polarity network. J Exp Zool 2002;294:216-51.

Tips and Tricks For Boosting Your Metabolism

Tips and Tricks For Boosting Your Metabolism

So maybe instead of being a pencil-neck dweeb, youre a bit of a fatty. Well, thats no problem either. Because this bonus will show you exactly how to burn that fat off AS you put on muscle. By boosting your metabolism and working out the way you normally do, you will get rid of all that chub and gain the hard, rippled muscles youve been dreaming of.

Get My Free Ebook


Post a comment